Davis Polk is advising Bio-Reference Laboratories, Inc. in connection with its approximately $1.47 billion acquisition by OPKO Health, Inc. Under the terms of the agreement, holders of Bio-Reference Laboratories common stock will receive 2.75 shares of OPKO common stock for each share of Bio-Reference Laboratories common stock. The transaction, which is expected to be completed during the second half of 2015, is subject to approval of Bio-Reference Laboratories’ shareholders and other customary conditions. 

Bio-Reference Laboratories is one of the largest and fastest-growing full-service diagnostic laboratories in the world, providing clinical testing services to physician offices, clinics, hospitals, long term care facilities and employers while also advancing drug discovery and development with disease foundations, academic and pharmaceutical partners. OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.

The Davis Polk corporate team includes partners David L. Caplan and John H. Butler and associates Laura C. Turano and Nicholas J. Marricco. Partner Jean M. McLoughlin is providing executive compensation advice. Partner Kathleen L. Ferrell is providing tax advice. Partner Frank J. Azzopardi is providing intellectual property advice. Partner Jon Leibowitz is providing antitrust and competition advice. Counsel Scott B. Luftglass is providing litigation advice. Members of the Davis Polk team are based in the New York and Washington DC offices.

Copy link to share post